{"id":"W2174132185","doi":"10.1016/s0140-6736(15)00388-8","title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","year":2015,"lang":"en","type":"article","venue":"The Lancet","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":566,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Eczema Area and Severity Index; Dupilumab; Medicine; Atopic dermatitis; Blinding; Placebo; Dermatology Life Quality Index; Randomized controlled trial; Clinical trial; Internal medicine; Adverse effect; SCORAD; Placebo-controlled study; Clinical endpoint; Dermatology; Double blind; Disease; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003313577,0.0001963316,0.00156848,0.00006923603,0.00006115158,0.00001781243,0.0001119878,0.00008733417,0.00003322065],"category_scores_gemma":[0.0005164794,0.0001091104,0.00008359746,0.0001083587,0.000102418,0.00006733323,0.00002496963,0.0001524402,0.000007092225],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004403618,"about_ca_system_score_gemma":0.0001188398,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005128116,"about_ca_topic_score_gemma":0.00003294049,"domain_scores_codex":[0.9984999,0.0003290945,0.0004656286,0.0002090423,0.0002070366,0.000289354],"domain_scores_gemma":[0.9987445,0.0006001552,0.0001283017,0.0002945614,0.00005660777,0.0001759133],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9903394,0.0006633583,0.001674381,0.00006003694,0.0003789311,0.0001243014,0.001029903,0.00004050113,0.000009289988,0.00007044311,0.003837703,0.001771761],"study_design_scores_gemma":[0.9937927,0.001140699,0.001988376,0.0002893549,0.0003659398,0.00009315107,0.0001834457,0.001548745,0.00005927193,0.0001009648,0.0003169813,0.0001203317],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9875292,0.001352655,0.0001172689,0.004141821,0.00006703338,0.004699625,0.00003431273,0.00003334341,0.002024711],"genre_scores_gemma":[0.9980498,0.00010283,0.0001010341,0.0008801032,0.0001337146,0.0004271286,0.00003417696,0.00001286321,0.0002583617],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01052056,"threshold_uncertainty_score":0.4449393,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01984300005220019,"score_gpt":0.2878115342263952,"score_spread":0.267968534174195,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}